此页面是自动翻译的，不保证翻译的准确性。请参阅英文版对于源文本。

PET-MR Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis With 64Cu-NODAGA-CANF (Multisite)

2026年10月29日更新者：Washington University School of Medicine

PET-MR Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis With 64Cu-NODAGA-CANF

The goal of this clinical trial is to evaluate the feasibility of imaging atherosclerosis by 64Cu-NODAGA-CANF PET-MR in a pilot study of patients with asymptomatic carotid artery stenosis (ACAS). The main question it aims to answer is:

Can 64Cu-NODAGA-CANF PET detect carotid atherosclerosis in patients with ACAS?

Uptake of 64Cu-NODAGA-CANF as measured by PET-MR will also be correlated to anatomic features of plaque on MRI, outcomes for patients treated with optimal medical therapy (OMT) alone or OMT and carotid endarterectomy (CEA) surgery, and tissue measurements for patients undergoing CEA surgery. The ability of 64Cu-NODAGA-CANF to risk stratify ACAS patients treated with OMT alone with respect to patient outcomes will be determined.

Participants will

Receive a single intravenous (IV) administration of 64Cu-NODAGA-CANF followed by dynamic PET-MR imaging for up to 60 minutes and a second optional scan between 1-4 hours post-injection.
Undergo physical examinations, vital sign measurements, and blood and urine collection for clinical laboratory tests.
Undergo standard of care treatment with either OMT alone or OMT and CEA surgery.
Be evaluated with phone interviews 48-72 hours (2-3 days) after discharge and every 3 months (+/- 5 days) to assess for ipsilateral ischemic cerebrovascular event (transient ischemic attack (TIA), stroke) or remote ipsilateral carotid intervention.

研究概览

地位

尚未招聘

条件

干预/治疗

药品：64Cu-NODAGA-CANF

详细说明

This study is a Phase 1, multicenter, open-label baseline controlled imaging study designed to assess whether 64Cu-NODAGA-CANF PET-MR can detect carotid atherosclerosis in patients with ACAS. A total of 30 subjects, both men and women (≥18 years of age), will be recruited at Washington University and Cedars Sinai, with approximately 25 patients recruited at Washington University and approximately 5 patients recruited at Cedars Sinai. Patients will receive a single intravenous (IV) bolus injection of 8-10 mCi of the investigational radiotracer 64Cu-NODAGA-CANF followed by dynamic PET-MR imaging for up to 60 minutes and a second optional scan between 1-4 hours post-injection. Patients will undergo 64Cu-NODAGA-CANF PET-MR imaging of both carotid arteries. Both carotid arteries will be imaged at the same time.

At the time of imaging, the investigators will record baseline medications to include any antiplatelet, statin, anti-hypertension, and diabetes medications (OMT), as well as basic risk factors and social history (e.g. diabetic, hypertensive, smoker, hypercholesterolemia). A physical examination will be performed at screening and prior to discharge. Vital signs will be obtained at baseline pre-injection, post-injection following each imaging session, and prior to discharge. Blood will be drawn at screening or baseline and prior to discharge to assess for interval change in serum chemistries and complete blood count. Urine will be collected at screening or baseline and prior to discharge to assess for interval change in urinalysis results. Blood samples will be obtained from all subjects at Washington University for radiolabeled metabolite analysis. Two-mL blood samples will be obtained at screening/baseline pre-injection and at 5 minutes and 30 minutes post 64Cu-NODAGA-CANF injection.

Telephone follow-up will occur within 48-72 hours (2-3 days) after discharge and every 3 months (+/- 5 days) to assess for ipsilateral ischemic cerebrovascular event (transient ischemic attack (TIA), stroke) or remote ipsilateral carotid intervention.

We hope to demonstrate differences in PET SUV (Standardized Uptake Value) in the significantly atherosclerotic artery in comparison to the PET SUV in the artery that is not significantly diseased.

We will also determine whether PET SUV of 64Cu-NODAGA-CANF correlates to anatomic features of plaque on MRI. The presence and volumes of various plaque components including lipid pool, fibrous cap, and intraplaque hemorrhage will be determined from the MR images. We will determine the ability of 64Cu-NODAGA-CANF to risk stratify ACAS patients treated with OMT alone with respect to patient outcomes. PET signal will be assessed as a marker of risk for event or progression to CEA surgery in comparison to anatomic features of vulnerable plaque on MRI, with the goal of determining 64Cu-NODAGA-CANF PET signal above which suggests ACAS at higher risk for causing stroke. In patients who undergo CEA surgery, the ex vivo post-operative plaque specimen will be collected and PET uptake will be correlated to tissue measurements including the American Heart Association classifications of atherosclerosis and tissue presence of NPR-C.

研究类型

观察性的

注册 (估计的)

联系人和位置

本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。

学习联系方式

姓名：Molly Mohrman
电话号码：314-747-4633
邮箱：mohrmanm@wustl.edu

研究联系人备份

姓名：Pamela K. Woodard, MD
电话号码：314-362-7100
邮箱：woodardp@wustl.edu

学习地点

美国
- California
  - Los Angeles、California、美国、90048
    - Cedars Sinai Medical Center
    - 接触：
      
      Yibin Xie, PhD
      
      电话号码：310-248-8674
      
      邮箱：Yibin.Xie@cshs.org
    - 首席研究员：
      
      Yibin Xie, PhD
- Missouri
  - St Louis、Missouri、美国、63110
    - Washington University School of Medicine
    - 接触：
      
      Pamela K. Woodard, MD
      
      电话号码：314-362-7100
      
      邮箱：woodardp@wustl.edu
    - 首席研究员：
      
      Pamela K. Woodard, MD

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Individuals ≥18 years of age with asymptomatic carotid artery stenosis.

描述

Inclusion Criteria:

Adults, 18 years of age or older.
Asymptomatic carotid artery stenosis patients who have undergone carotid Doppler/ultrasound imaging or other carotid imaging which have demonstrated a ≥ 60% diameter carotid artery stenosis.
The treating surgeon has planned either treatment with optimal medical therapy (OMT) alone or OMT and carotid endarterectomy (CEA) surgical intervention.

Exclusion Criteria:

Inability to receive and sign informed consent.
Patients with an unstable clinical condition that in the opinion of the Sponsor-Investigator or designee precludes participation in the study.
Inability to tolerate up to 60 minutes in a supine position with arms down at sides for PET-MR imaging.
Prior history of carotid endarterectomy (CEA) or carotid artery stent procedure on the ipsilateral side.
Past medical history of transient ischemic attack (TIA) or stroke within the last 6 months.
Unwilling to comply with study procedures and/or unable to be available for the duration of the study outlined in the protocol.
Claustrophobia or other preventing condition that has previously or would interfere with completion of imaging as outlined in the protocol.
Participation in another research study with an investigational drug, including a diagnostic or therapeutic radiopharmaceutical, currently or within the last year.
Contraindications to MR imaging (pacemaker, brain aneurysm clips, shrapnel, claustrophobia, etc.).
Currently pregnant or lactating. All female subjects of childbearing potential must have a documented negative pregnancy test (serum or urine hCG) performed within 24 hours immediately prior to the administration of 64Cu-NODAGA-CANF or documented post-menopausal defined as the cessation of menses for ≥ 12 months or documentation of having a bilateral oophorectomy and/or hysterectomy.

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

观测模型：COHORT
时间观点：PROSPECTIVE

团体/队列数

队列和干预

团体/队列	干预/治疗
Patients treated with Optimal Medical Therapy (OMT) alone Asymptomatic carotid artery stenosis (ACAS) patients with known carotid artery atherosclerosis by ultrasound/Doppler or other carotid imaging with ≥ 60% diameter stenosis who are clinically referred for OMT alone.	药品：64Cu-NODAGA-CANF Patients will receive a single intravenous (IV) injection of 8-10 mCi of 64Cu-NODAGA-CANF for PET-MR imaging at the imaging visit.
Patients treated with OMT and carotid endartarectomy (CEA) Asymptomatic carotid artery stenosis (ACAS) patients with known carotid artery atherosclerosis by ultrasound/Doppler or other carotid imaging with ≥ 60% diameter stenosis who are clinically referred for OMT and CEA.	药品：64Cu-NODAGA-CANF Patients will receive a single intravenous (IV) injection of 8-10 mCi of 64Cu-NODAGA-CANF for PET-MR imaging at the imaging visit.

研究衡量的是什么？

主要结果指标

结果测量	措施说明	大体时间
Comparison of 64Cu-NODAGA-CANF PET SUV (Standardized Uptake Value) between the atherosclerosis of the target diseased carotid artery and the non-diseased contralateral carotid artery or non-diseased vertebral artery 大体时间：Up to 4 hours post-injection of 64Cu-NODAGA-CANF	PET uptake of 64Cu-NODAGA-CANF will be quantified as SUV. For each subject, PET SUV will be measured in the atherosclerosis of the diseased carotid artery and in a region of non-disease in the contralateral carotid artery, or if the contralateral carotid is completely diseased, a portion of non-diseased vertebral artery. Mean SUV in the atherosclerosis of the diseased carotid arteries will be compared to mean SUV in the non-diseased contralateral carotid arteries or non-diseased vertebral arteries.	Up to 4 hours post-injection of 64Cu-NODAGA-CANF

次要结果测量

结果测量	措施说明	大体时间
Correlation of 64Cu-NODAGA-CANF PET uptake to American Heart Association (AHA) stage of atherosclerotic plaque as determined by MRI 大体时间：Up to 4 hours post-injection of 64Cu-NODAGA-CANF	Patients with carotid atherosclerosis will be imaged with 64Cu-NODAGA-CANF PET-MR. MRI is acquired simultaneously with 64Cu-NODAGA-CANF PET. MR images will be evaluated for AHA plaque stage. PET uptake of 64Cu-NODAGA-CANF will be quantified as SUV. PET signal (SUV) will be compared between patients with different AHA stages of atherosclerotic plaque.	Up to 4 hours post-injection of 64Cu-NODAGA-CANF
Correlation of 64Cu-NODAGA-CANF PET uptake to absence or presence of atherosclerosis as determined by MRI 大体时间：Up to 4 hours post-injection of 64Cu-NODAGA-CANF	Patients with carotid atherosclerosis will be imaged with 64Cu-NODAGA-CANF PET-MR. MRI is acquired simultaneously with 64Cu-NODAGA-CANF PET. MR images will be evaluated for absence or presence of atherosclerosis. PET uptake of 64Cu-NODAGA-CANF will be quantified as SUV. PET signal (SUV) will be compared between patients with absence or presence of atherosclerosis.	Up to 4 hours post-injection of 64Cu-NODAGA-CANF
Correlation of 64Cu-NODAGA-CANF PET uptake to absence or presence of lipid core as determined by MRI 大体时间：Up to 4 hours post-injection of 64Cu-NODAGA-CANF	Patients with carotid atherosclerosis will be imaged with 64Cu-NODAGA-CANF PET-MR. MRI is acquired simultaneously with 64Cu-NODAGA-CANF PET. MR images will be evaluated for absence or presence of lipid core. PET uptake of 64Cu-NODAGA-CANF will be quantified as SUV. PET signal (SUV) will be compared between patients with absence or presence of lipid core.	Up to 4 hours post-injection of 64Cu-NODAGA-CANF
Correlation of 64Cu-NODAGA-CANF PET uptake to absence or presence of hemorrhage as determined by MRI 大体时间：Up to 4 hours post-injection of 64Cu-NODAGA-CANF	Patients with carotid atherosclerosis will be imaged with 64Cu-NODAGA-CANF PET-MR. MRI is acquired simultaneously with 64Cu-NODAGA-CANF PET. MR images will be evaluated for absence or presence of hemorrhage. PET uptake of 64Cu-NODAGA-CANF will be quantified as SUV. PET signal (SUV) will be compared between patients with absence or presence of hemorrhage.	Up to 4 hours post-injection of 64Cu-NODAGA-CANF
Correlation of 64Cu-NODAGA-CANF PET uptake to outcomes 大体时间：Up to 4 years following PET-MR imaging	PET uptake of 64Cu-NODAGA-CANF will be quantified as SUV. We will determine the ability of 64Cu-NODAGA-CANF to risk stratify ACAS patients with respect to patient outcomes. Patients will be contacted every 3 months after PET-MR imaging to assess for interval ipsilateral ischemic cerebrovascular event (transient ischemic attack (TIA), stroke) or remote ipsilateral carotid intervention. PET signal will be assessed as a marker of risk for event or progression to CEA surgery. 64Cu-NODAGA-CANF PET signal (SUV) will compared between patients who experienced or did not experience an ipsilateral ischemic cerebrovascular event (TIA, stroke) or remote ipsilateral carotid intervention (carotid endarterectomy (CEA) surgery or stent placement).	Up to 4 years following PET-MR imaging
Correlation of 64Cu-NODAGA-CANF PET uptake to American Heart Association (AHA) stage of atherosclerotic plaque as determined by histology on ex vivo tissue specimens for patients undergoing CEA surgery 大体时间：Immediately after surgery	PET uptake of 64Cu-NODAGA-CANF will be quantified as SUV. In patients who undergo CEA, the ex vivo post-operative plaque specimen will be collected. Tissue measurements will include American Heart Association (AHA) plaque stage as an indicator of plaque vulnerability. AHA stage of atherosclerotic plaque will be determined by assessment of hematoxylin and eosin (H&E), Verhoeff-Van Gieson (VVG), and pentachrome stained specimens. 64Cu-NODAGA-CANF PET signal (SUV) obtained from images pre-surgery will be compared between patients with different AHA stages of atherosclerotic plaque on the surgical tissue specimen.	Immediately after surgery
Correlation of 64Cu-NODAGA-CANF PET uptake to expression of targeted receptor, NPR-C, by immunohistochemistry on ex vivo tissue specimens for patients undergoing CEA surgery 大体时间：Immediately after surgery	PET uptake of 64Cu-NODAGA-CANF will be quantified as SUV. In patients who undergo CEA, the ex vivo post-operative plaque specimen will be collected. Tissue measurements will include expression of NPR-C by immunohistochemistry. 64Cu-NODAGA-CANF PET signal (SUV) obtained from images pre-surgery will be correlated to expression of NPR-C on the surgical tissue specimen.	Immediately after surgery

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

Washington University School of Medicine

合作者

National Heart, Lung, and Blood Institute (NHLBI)

Cedars-Sinai Medical Center

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年11月18日

初级完成 (估计的)

2027年5月31日

研究完成 (估计的)

2027年5月31日

研究注册日期

首次提交

2026年10月29日

首先提交符合 QC 标准的

2026年10月29日

首次发布 (实际的)

2026年11月4日

研究记录更新

最后更新发布 (实际的)

2026年11月4日

上次提交的符合 QC 标准的更新

2026年10月29日

最后验证

2026年10月1日

PET-MR Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis With 64Cu-NODAGA-CANF (Multisite)